Retour au classement

LifeStance Health Group, Inc. (LFST)

NEUTRAL
HealthcareMedical Care FacilitiesUnited States

Fondamental

60

Prix

$12.07

Capitalisation boursière

$4.75B

Partie 1 · Ce que vaut l'entreprise

Vue d'ensemble

LifeStance Health Group, Inc., through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a multidisciplinary suite of mental health services, psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy. It also treats a range of mental health conditions, including anxiety, depression, bipolar disorder, eating disorders, psychotic disorders, and post-traumatic stress disorder. In addition, the company operates an outpatient mental health platform, as well as offers patient care virtually through its online delivery platform or in-person at its centers. LifeStance Health Group, Inc. was founded in 2017 and is headquartered in Scottsdale, Arizona.

No editorial profile for this company yet

Direct competitors

Who this company fights with for the same customers

No editorial profile for this company yet

No competitor list for this company yet.

Bilan & Liquidités

Chiffre d'affaires

$1.58B

12 derniers mois (au 30/06/2026)

Résultat net

$51M

12 derniers mois (au 30/06/2026)

Flux de trésorerie libre

$110M

Capitaux propres totaux

$1.52B

Passif total

$683M

Ratio de liquidité général

1.38

Couverture des intérêts

7.75

Dette/EBITDA

7.21

Bénéfice par action

Chiffre d'affaires & Résultat net

Flux de trésorerie libre

Décomposition du résultat

État historique

Marges dans le temps

La dette dans le temps

Le poids de la dette

Grille de la croissance

Croissance — Chiffre d'affaires

Estimation de la juste valeur

General caseJustement valorisé

Juste valeur

$10.62

Prix actuel

$12.07

Marge de sécurité

-13.7%

Fourchette de juste valeur

$6.90 - $14.33

Méthodes d'estimation

Analyst price target:$13.80
Discounted cash flow (DCF):$4.51
Earnings multiple (P/E):$6.92
Graham growth formula:$2.12
Earnings power value (EPV):$0.78
Justified P/B:Not enough data to compute it
Dividend discount (Gordon):Not enough data to compute it
P/FFO, funds from operations:Not enough data to compute it
Mid-cycle earnings:Not enough data to compute it
Revenue multiple:Not enough data to compute it
Consensus des analystes:Achat fort (14B / 4H / 0S)
Dernière surprise sur les résultats:+34.53%

Indicateurs de valorisation

Ratio P/E

93.54

ROE

0.6%

Ratio P/B

3.15

P/FCF

26.71

Marge brute

-

ROIC

3.3%

Radar de rentabilité

Value Creation (Economic Moat)

ROIC

3.3%

WACC

10.4%

ROIC − WACC

-7.2 pp

ROIC is below the cost of capital — the company is destroying value for every dollar invested.

Critères d'analyse fondamentale

Réussi (14)

  • EPS shows upward trend
  • Price CAGR 5.55%
  • P/FCF 26.71
  • Debt/Equity ratio
  • Positive Free Cash Flow
  • Current Ratio
  • Interest Coverage
  • Return on Tangible Assets
  • Revenue Growth 5Y 30.4%
  • Analyst Consensus 78% Buy
  • Earnings Surprise avg 621.9%
  • Earnings Quality (OCF/NI) 4.31
  • Net Margin Trend 3.2% vs -1.2%
  • Piotroski F-Score 7/9

Échoué (10)

  • ROIC 3.2%
  • P/B Ratio 3.15
  • Operating Margin 4.9%
  • CapEx intensity
  • Debt/EBITDA
  • Low reliance on intangibles
  • Price below Graham Number
  • DCF valuation (Overvalued)
  • ROE 1.6%
  • Share Dilution 26.2%

Indisponible (3)

  • Gross Margin NaN%
  • Dividend Payout NaN%
  • PEG Ratio (need PE > 0 and growth > 0)

Score F de Piotroski

7/9

Santé financière solide

score
criteria

Qualité des bénéfices

4.31

Qualité élevée : bénéfices soutenus par la trésorerie

Dilution du capital

26.2%

Émission de nouvelles actions, diluant la participation

Gouvernance

Équipe dirigeante

NomTitreÂge
Mr. Kenneth Alan Burdick J.D.Executive Chairman66
Mr. David Patrick BourdonCEO & Director56
Mr. Ryan Bruce McGroartyCFO & Treasurer52
Mr. Vukasin PaunovichChief Technology Officer53
Mr. Ryan Pardo J.D.Chief Legal Officer & Secretary48
Ms. Ann VaranakisChief People Officer47
Ms. Lisa Keise MillerChief Operating Officer & Principal Operating Officer51
Ms. Monica ProkockiVice President of Investor Relations-
Brooke MatthewsDirector of Public Relations-
Mr. Richard HallChief Shared Services Officer-

Risque d'audit

10

Risque du conseil

10

Risque de rémunération

7

Risque droits des actionnaires

8

Partie 2 · Le prix et le moment d'entrer

Cette partie ne dit pas si l'entreprise vaut la peine : elle aide à choisir quand l'acheter, une fois que les fondamentaux vous ont convaincu. À l'intérieur : analyse technique, potentiel, baisses historiques, exposition gamma.

Latest News

Recent headlines for LFST, sourced from Markets Gazette.

  • 2/25/2026NEUTRAL
    LifeStance (LFST) Q4 2025 Earnings Call Transcript

    The transcript for LifeStance Health Group, Inc.'s (LFST) Q4 2025 earnings call is now available. Investors and analysts have been keenly awaiting this document to gain in-depth insights into the company's financial performance for the period. While the specific content has not been disclosed in this announcement, the release of the transcript is a crucial event for market transparency. Market participants will now focus on analyzing management's statements, future projections, and responses to analyst questions to assess LifeStance's operational health and growth prospects. The market's reaction will hinge on the key metrics presented and the guidance provided.

via Markets Gazette